baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Werewolf Therapeutics/ US95075A1079 /

08/07/2024 21:59:27	Chg. +0.11	Volume	Bid-	Ask-	High	Low
2.19USD	+5.02%	15,244 Turnover: 32,377.51	-Bid Size: -	-Ask Size: -	2.19	2.03

GlobeNewswire 25/06 Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical ...

GlobeNewswire 01/06 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...

GlobeNewswire 30/05 Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire 23/05 Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monothera...

GlobeNewswire 03/05 Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 24/04 Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 Amer...

GlobeNewswire 23/04 Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Pot...

GlobeNewswire 05/04 Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammat...

GlobeNewswire 04/04 Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform...

GlobeNewswire 07/03 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busin...

GlobeNewswire 06/03 Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

GlobeNewswire 05/03 Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

GlobeNewswire 08/01 Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

GlobeNewswire 04/01 Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

GlobeNewswire 22/11/2023 Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

GlobeNewswire 14/11/2023 Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 03/11/2023 Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establish...

GlobeNewswire 31/10/2023 Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of C...

GlobeNewswire 27/09/2023 Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s ...

GlobeNewswire 11/09/2023 Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

GlobeNewswire 05/09/2023 Werewolf Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 24/03/2022 Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides ...

GlobeNewswire 16/03/2022 Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-12...

GlobeNewswire 15/03/2022 Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting

GlobeNewswire 08/02/2022 Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

Werewolf Therapeutics/ US95075A1079 /

If you wish to receive reply to your feedback, please provide your email address.